Oncolytic Adenovirus E1A/E3/E4 Edits for Tumor-Selective Replication

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current oncolytic adenoviral therapies face challenges in selectively replicating in cancer cells with high efficiency and safety, often failing to effectively treat advanced cancer due to limitations in virus potency and selectivity.

Innovation Solution

Recombinant adenoviruses with modifications in the E1A, E3, and E4 regions, including deletions of specific E3 genes and E4orf6/7, enhance replication in tumor cells while detargeting from normal cells, using a chimeric fiber protein for retargeting and incorporating a heterologous open reading frame.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If oncolytic adenoviruses are designed to selectively replicate in cancer cells, then tumor cell specificity is improved, but replication efficiency in tumor cells deteriorates

Engineering Contradiction:

Improvetumor cell specificityVSAvoidreplication efficiency

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The adenovirus genome is segmented into multiple functional regions (E1A, E3, E4) with specific modifications in each. The E1A region contains mutations (Q31L, Q31L/A88V) that enhance replication in cancer cells, the E3 region has deletions (12.5k, 6.7k, 19k genes) to improve tumor selectivity, and the E4 region has deletions (E4orf6, E4orf7) to enhance replication efficiency. This segmentation allows independent optimization of each region to simultaneously achieve both specificity and efficiency.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

Specific amino acid substitutions are introduced at localized positions within the E1A protein (Q31L at position 31, A88V at position 88) to confer cancer cell-selective replication properties. These localized mutations alter the protein's interaction with cellular targets in a way that specifically enhances replication in transformed cells while maintaining safety in normal cells, thereby improving both specificity and replication efficiency locally within the viral structure.

Inventive Principle:

Principle #3Local quality

2Productivity

If oncolytic adenoviruses are designed to replicate in tumor cells, then anti-tumor activity is improved, but safety profile deteriorates due to liver toxicity

Engineering Contradiction:

Improveanti-tumor activityVSAvoidliver toxicity

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

Instead of modifying the virus to actively target tumor cells through ligand-receptor interactions, the invention inverts the approach by deleting genes (E3 12.5k, 6.7k, 19k; E4orf6, E4orf7) that are responsible for liver tropism and toxicity. This creates a virus that is inherently excluded from liver cells, thereby improving safety while maintaining or enhancing anti-tumor activity through selective replication in cancer cells with defective antiviral responses.

Inventive Principle:

Principle #13The other way round (Inversion)

Data Source

PatentUS12365878B2Oncolytic adenovirus with enhanced replication properties comprising modifications in E1A, E3, and E4

Publication Date: 2025.07.22 SALK INST FOR BIOLOGICAL STUDIES

AI summary

Tumor-selective recombinant adenoviruses that possess deletions or modifications in the E3 region are described. Recombinant adenoviruses that express adenovirus death protein (ADP) but have a deletion of at least three of the remaining six E3 genes exhibit enhanced virus replication. The recombinant adenoviruses further include additional modifications to allow selective replication in tumor cells and to detarget viruses from the liver. Use of the recombinant adenoviruses for cancer treatment is described.